文献速递糖尿病

FreeStyle Libre Pro iQ 在症状前 1 型糖尿病中的应用

Continuous glucose monitoring using the FreeStyle Libre Pro iQ in presymptomatic type 1 diabetes.
PubMed 文献 · Diabetologia · 2026-09-07

研究纳入 50 名无胰岛自身抗体的对照儿童青少年与 89 名早期(1 或 2 期)1 型糖尿病患儿,使用 FreeStyle Libre Pro iQ 进行持续葡萄糖监测(CGM)。CGM 参数在无早期、1 期与 2 期 1 型糖尿病者间及单个与多个血糖异常者间存在显著差异,且 97.5 百分位阈值有助于识别快速进展者,但需注意系统特异性解读。

要点

  • CGM 参数在 1 型糖尿病早期分期及血糖异常程度间存在显著差异。
  • 97.5 百分位阈值有助于识别 1 年内进展至临床糖尿病的高风险个体。
  • FreeStyle Libre Pro iQ 与 Dexcom G6 的 CGM 值差异明显,需系统特异性解读。

核心结论

  • CGM 是早期 1 型糖尿病分期和风险分层的有前景工具。
  • 在用于治疗决策前需进行系统特异性解读。

研究设计与样本

  • 2023 年 12 月至 2025 年 12 月,纳入 50 名无胰岛自身抗体的对照儿童青少年和 89 名早期(1 或 2 期)1 型糖尿病患儿,使用 FreeStyle Libre Pro iQ 进行 CGM。
  • 对早期 1 型糖尿病参与者随访至进展为 3 期临床 1 型糖尿病。

主要发现

  • CGM 参数(SD、CV、TA140、TA160、time in tight range)在无早期、1 期、2 期 1 型糖尿病者间及单个与多个血糖异常者间存在显著差异。
  • 1 期 1 型糖尿病者中 10/45(22%)有至少一个参数超过对照 97.5 百分位,2 期者中 13/25(52%)超过(p=0.017)。
  • 1 期者中 6/45(13%)有两个或以上参数超过 97.5 百分位,2 期者中 11/25(44%)超过(p=0.0077)。
  • TA140 的 97.5 百分位阈值(>15%)在 1 期者中无人超过,2 期者中 10/25(40%)超过,1 年内进展至临床糖尿病者中 6/8 超过。
  • FreeStyle Libre Pro iQ 值与 Dexcom G6 在类似队列中的既往观察值差异明显;使用对照 97.5 百分位定义 CGM 异常可实现系统间协调,识别 1 年内进展者的敏感性为 75%–100%(FreeStyle Libre Pro iQ)和 50%–100%(Dexcom G6)。

关键数值与推荐

  • CGM 异常定义为参数超过对照个体值的 97.5 百分位。
  • TA140 的 97.5 百分位阈值为 >15%。

临床怎么用

  • CGM 可用于早期 1 型糖尿病分期和风险分层。
  • 使用 CGM 进行临床决策前需考虑监测系统的特异性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of the study was to evaluate the ability of the FreeStyle Libre Pro iQ continuous glucose monitoring (CGM) system to discriminate between presymptomatic stages of type 1 diabetes and stratify progression to stage 3 type 1 diabetes. The study also aimed to compare the performance of the FreeStyle Libre Pro iQ with that of the Dexcom G6. METHODS: From December 2023 to December 2025, 50 children and adolescents without islet autoantibodies (control participants) and 89 with early-stage (stage 1 or 2) type 1 diabetes underwent CGM with the FreeStyle Libre Pro iQ. Participants with early-stage type 1 diabetes were followed up for the development of stage 3 clinical type 1 diabetes. RESULTS: CGM data were unavailable or incomplete for 13 participants (9%), leaving 126 (91%) for analysis (73 female, median age 10.0 years [IQR 7.9-12.8]). The CGM parameters used-namely the SD, CV, time with glucose levels above 7.8 mmol/l (140 mg/dl; TA140) and 8.9 mmol/l (160 mg/dl; TA160) and time in tight range-differed significantly across participants with no early-stage, stage 1 or stage 2 type 1 diabetes, and between participants with a single dysglycaemia abnormality and those with multiple dysglycaemia abnormalities. One or more of these parameters exceeded the 97.5th percentile of control values in 10 (22%) of the 45 individuals with stage 1 type 1 diabetes and in 13 (52%) of the 25 individuals with stage 2 type 1 diabetes (p=0.017). Two or more of the parameters exceeded the 97.5th percentile threshold in six (13%) of the individuals with stage 1 type 1 diabetes and 11 (44%) of the individuals with stage 2 type 1 diabetes (p=0.0077). The 97.5th percentile threshold for TA140 (i.e. >15%) was exceeded by none of the 45 individuals with stage 1 type 1 diabetes, 10 (40%) of the 25 individuals with stage 2 type 1 diabetes and six of the eight individuals who progressed to clinical diabetes within 1 year, identifying these individuals as rapid progressors. FreeStyle Libre Pro iQ values differed markedly from those previously observed using the Dexcom G6 in a similar cohort. Using the 97.5th percentile of values of control individuals to define CGM abnormalities enabled harmonisation across systems and supported the consistent identification of high-risk individuals. With this approach, the sensitivity for identifying those who progressed to clinical diabetes within 1 year ranged from 75% to 100% for the FreeStyle Libre Pro iQ and from 50% to 100% for the Dexcom G6. CONCLUSIONS/INTERPRETATION: These findings support CGM as a promising tool for staging and risk stratification in early-stage type 1 diabetes, while highlighting the need for system-specific interpretation before use in therapeutic decision-making.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Weiss A, Huber E, Reinmüller F, et al. Continuous glucose monitoring using the FreeStyle Libre Pro iQ in presymptomatic type 1 diabetes. Diabetologia. 2026. PMID: 42704479. doi:10.1007/s00125-026-06852-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。